Dr. David M. Mintzer, MD
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Medical school
- Jefferson Medical College of Thomas Jefferson University (1977)
- Years since graduation
- 49
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 804
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1977Medical school: Jefferson Medical College of Thomas Jefferson University
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
PA license MD021663E
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Hospital of Univ of Pennsylvania Philadelphia, PA
- Penn Presbyterian Medical Center Philadelphia, PA
- Chester County Hospital West Chester, PA
- Pennsylvania Hospital Philadelphia, PA
- Doylestown Hospital Doylestown, PA
Medical groups
- University of Penn - Medical Group (3,505 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 804
- Services billed
- 2,509
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 774 | 452 |
| Established patient office or other outpatient visit, 40-54 minutes | 267 | 131 |
| Established patient office or other outpatient visit, 20-29 minutes | 215 | 177 |
| New patient office or other outpatient visit, 45-59 minutes | 109 | 109 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 61 | 26 |
| New patient office or other outpatient visit, 60-74 minutes | 35 | 35 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 34 | 15 |
| New patient office or other outpatient visit, 30-44 minutes | 25 | 25 |
| Biopsy and aspiration of bone marrow sample for diagnosis | 19 | 18 |
| Hospital discharge day management, 30 minutes or less | 14 | 14 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Anastrozole Other prescribers in Philadelphia, PA | 192 |
| Letrozole Other prescribers in Philadelphia, PA | 98 |
| Oxycodone Hcl Other prescribers in Philadelphia, PA | 41 |
| Eliquis (apixaban) Other prescribers in Philadelphia, PA | 39 |
| Hydroxyurea Other prescribers in Philadelphia, PA | 37 |
| Brukinsa (zanubrutinib) | 35 |
| Calquence (acalabrutinib maleate) | 34 |
| Prednisone Other prescribers in Philadelphia, PA | 34 |
| Nubeqa (darolutamide) | 29 |
| Ibrance (palbociclib) | 27 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 2 companies. The companies reported $182,593 in research payments for these studies, mostly to the institutions running them.
- CAMBRIA-2 A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase In…
AstraZeneca UK Limited - CAMBRIA-1 A Phase III, Open-Label,Randomised Study to Assess the Efficacy and Safety of Extended Therapy with Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine …
AstraZeneca UK Limited - DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]
Daiichi Sankyo Inc. · Completed · NCT03523585
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.